Skip to content
etf.net

Launched · SEC filings

Global X - Genomics & Biotechnology ETF

GNOMNasdaqC

$65.34−1.30 (−1.95%)

At close: Oct 13, 2026, 4:00 PM

C40/ 100

Rank 11 of 17 in Biotech & Genomics

C40/100Rank 11 of 17inBiotech & Genomics
Intraday session: down, 77 prints from 66.64 to 65.34. Range 64.88 to 66.05. Use the arrow keys to read each point.65.0065.7566.0066.2510 AM12 PM2 PM4 PM
Expense ratio
0.50%
Fund size
$104M
1Y total return
+64.9%
Yield · Last 12 months
0.97%
Holdings
51
Avg volume · 30D
0M sh
NAV per share
$68.47
52W range
low $40.17high $74.19
Launched
Filings
SEC EDGAR

The ETF.net GNOM Grade

Based on 5 of 6 pillars

C

Score 40 out of 100

Category
Biotech & Genomics⁠
Rank
11 of 17
Six-pillar profile for GNOM. Scores out of 100: Cost 38, Risk 33, Mission not scored, Tradability 53, Holdings 36, Durability 51. Strongest: Tradability (53). Weakest: Risk (33). Based on 5 of 6 pillars.

Score 40 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    D38 out of 100
    Rank 10 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    D33 out of 100
    Rank 13 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    C53 out of 100
    Rank 8 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    D36 out of 100
    Rank 15 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    C51 out of 100
    Rank 10 of 17

Our read on GNOM

ETF.net Research

CMost biotech ETFs buy the whole drug industry. GNOM buys the genome: gene editing, sequencing, genetic therapies, computational genomics. About 50 global names, one idea, no hedging.

Stated mandate

GNOM seeks to track, before expenses, the performance of the Solactive Genomics Index by investing in companies positioned to benefit from advances in genomic science, including gene editing, sequencing, genetic therapies, computational genomics, and biotechnology.

Why people hold it

  1. 01A genuine pure play. The index targets companies tied to advances in genomic science (gene editing, sequencing, genetic therapies), not the broad pharma complex most biotech funds hold.globalxetfs.com
  2. 02Concentrated on purpose: roughly 50 holdings, global reach. The theme drives the fund instead of being diluted by megacap drugmakers.globalxetfs.com
  3. 03Running since 2019, it is one of the older dedicated genomics baskets, with a multi-year record through a full cycle in the theme.

Worth knowing

  1. 01The narrow screen costs more: 0.50% a year, against 0.44% for IBB, 0.35% for XBI and 0.19% for IBBQ, which own biotech broadly.
  2. 02Thinly traded next to the big biotech funds. Limit orders and mid-session trading matter more here than with a household-name ETF.
  3. 03Small, clinical-stage genomics names swing hard, and with about 50 holdings there is nowhere to hide. Volatility is the price of the pure theme.

GNOM Holdings

As of Oct 11, 2026
Asset class
Stocks
Holdings
51
Top-10 weight
56%
Largest holding
MRNA11.3%

Sectors

  • Health Care99.7%
  • Technology0.3%

Geography

  • United States85.15%
  • Hong Kong4.49%
  • Netherlands4.09%
  • Switzerland2.65%
  • Germany2.50%
  • United Kingdom1.13%
The fund’s holdings, weight-ordered — page 1 of 4.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001MRNAModerna Inc11.33%53,957$12M286
002TWSTTwist Bioscience Corp6.87%46,055$7M125
003TXG10X Genomics Inc-Class A6.67%88,623$7M137
004ILMNIllumina Inc5.97%22,989$6M322
005NTRANatera Inc5.40%14,432$6M238
006GHGuardant Health Inc5.24%33,493$6M175
0071548.HKGenscript Biotech Corp4.49%889,618$5M69
008TECHBio-Techne Corp3.46%51,203$4M186
009VRTXVertex Pharmaceuticals Inc3.27%6,858$3M422
010QGENQiagen N.v.3.18%75,059$3M50
011BMRNBiomarin Pharmaceutical Inc2.83%55,397$3M177
012CRSPCrispr Therapeutics AG2.65%53,173$3M81
013CAICaris Life Sciences Inc2.61%94,322$3M92
014VCYTVeracyte Inc2.57%60,992$3M140
015BNTXBiontech Se-Adr2.50%27,632$3M33

Showing 1–15 of 51 holdings

GNOM Performance

Launched Apr 5, 2019

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.
GNOM$16,485
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$12,044
Oct 10, 2025 to Oct 12, 2026. GNOM $16,485. SPY $12,044. Use the arrow keys to read each point.$9,116$13,825$18,535Oct 2025Apr 2026Oct 2026

Oct 10, 2025 – Oct 12, 2026

Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for GNOM. Periods over one year show the average yearly return.
PeriodGNOM
Year to date+46.7%
1 month+7.1%
3 months+17.6%
1 year+64.9%
3 yearsper year+20.6%
5 yearsper year−4.5%
10 yearsFund is under 10 years oldper year—

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for GNOM
YearReturn barGNOM
2026 YTD+46.7%
2025+18.7%
2024−16.0%
2023−8.6%
2022−36.3%
2021−15.9%
2020+51.5%

GNOM in the news

Filtered to GNOM · Biotech & Genomics

GNOM Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 12, 2026.
0.97%Last 12 months
Payout per share
$0.65Last 12 months
Last payment
$0.06 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Twice a year

Distribution history

2020–2026

One bar per payment. 5 payments from 2020 to 2026 YTD. Dec 30, 2020 $0.13; Dec 30, 2021 $0.03; Jun 27, 2025 $0.03; Dec 30, 2025 $0.59; Jun 29, 2026 $0.06. Use the arrow keys to read each point.2020202120222023202420252026YTD
Ex-datePay dateAmount per share
Jun 29, 2026Jul 7, 2026$0.06
Dec 30, 2025Jan 7, 2026$0.59
Jun 27, 2025Jul 7, 2025$0.03
Dec 30, 2021Jan 7, 2022$0.03
Dec 30, 2020Jan 8, 2021$0.13

GNOM Risk

How much the fund’s monthly returns vary, scaled to a year.
31.3%
Annualised · 36 months to Sep 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.61
vs 3-month T-bills · to Sep 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−68.9%
Trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
1.60
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

GNOM Cost

Expense ratio0.50%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

9 of the 17 Biotech & Genomics funds charge less.

GNOM costs $50.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.

Other funds in Biotech & Genomics

See others